Fabrication of Paclitaxel and 17AAG-loaded Poly-ε-Caprolactone Nanoparticles for Breast Cancer Treatment.
- 11 January 2021
- journal article
- Vol. 10 (1)
Abstract
The aim of this study is to design, fabricate and determine the cytotoxic effects of dual loaded paclitaxel and 17-AAG in stealth polymeric nanoparticles. The nanoparticles were fabricated by dispersion polymerization. Two breast cancer cell lines (MCF-7 and SKBR-3) were cultured and treated with media only, blank nanoparticles, paclitaxel (as a free drug), 17-AAG (free drug), paclitaxel + 17-AAG combination (as free drugs), and paclitaxel + 17-AAG combination loaded in poly-ε-caprolactone stealth nanoparticles. Each drug in the combination was half the concentration of the single free drug. The cytotoxic effects of the paclitaxel treatment and that of the combination (free drug) were found to be similar in both SKBR3 and MCF7 cell lines. Similar cytotoxic effects were observed for the drug combination both in the drug loaded nanoparticles formulation and in free drug form for both cell lines. Both paclitaxel and 17-AAG were effectively loaded and released from the polymeric nanoparticles. Paclitaxel (free drug), paclitaxel-17AAG combination (free drug), and dual drug-loaded nanoparticles had similar cytotoxic effects on both cell lines. Paclitaxel and 17-AAG combination resulted in synergistic effect: paclitaxel in the combination with 17-AAG was half its original concentration and yielded similar cytotoxic effect. The dose of paclitaxel was reduced without lowering its therapeutic efficacy.Keywords
This publication has 49 references indexed in Scilit:
- Potential applications and human biosafety of nanomaterials used in nanomedicineJournal of Applied Toxicology, 2017
- D-Optimal mixture experimental design for stealth biodegradable crosslinked docetaxel-loaded poly-ε-caprolactone nanoparticles manufactured by dispersion polymerization.2015
- Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's diseaseProgress in Neurobiology, 2011
- Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation StudyJournal of Clinical Oncology, 2007
- Optimizing Combination Chemotherapy by Controlling Drug RatiosMolecular Interventions, 2007
- The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteinsJCI Insight, 2007
- Paclitaxel Repackaged in an Albumin-Stabilized Nanoparticle: Handy or Just a Dandy?Journal of Clinical Oncology, 2005
- Targeting multiple signal transduction pathways through inhibition of Hsp90Journal of Molecular Medicine, 2004
- Repeat motifs of tau bind to the insides of microtubules in the absence of taxolThe EMBO Journal, 2003
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984